This protocol applies to patients with giant prolactinoma — a prolactin-secreting pituitary adenoma exceeding 40 mm with notable extrasellar extension — in whom prior dopamine agonist therapy did not achieve the required clinical goals.
Giant prolactinoma is defined by a diameter greater than 40 mm, notable extrasellar extension, and very high serum prolactin levels (usually >1,000 µg/l), with no concomitant GH or ACTH secretion. These tumours are rare and are predominantly observed in men.
Cabergoline (dopamine agonist) — medical management did not achieve the required targets: improved visual fields, normalised serum prolactin levels, and meaningful reduction in adenoma volume with notable mass size reduction. This protocol represents the step taken when those goals are not met.
DOI: 10.1038/s41574-023-00886-5
Giant prolactinomas are defined as those with a diameter >40 mm with notable extrasellar extension, very high serum levels of prolactin (usually >1,000 µg/l) and no concomitant GH or ACTH secretion.
Giant prolactinomas are rare and are predominantly observed in men; as they usually respond well to dopamine agonist therapy, they should be managed medically (strong).
Due to increased risk of morbidity and mortality, surgical resection of these large prolactinomas should be restricted to those with apoplexy or CSF leakage or to patients with progressive mass growth despite optimal treatment (strong).
View source ↗